ANTAZOLINE MESYLATE

First approved in 1948

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H19N3.CH4O3S
Molecular Weight	361.459
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.C(N(CC1=CC=CC=C1)C2=CC=CC=C2)C3=NCCN3

InChI

InChIKey=PIEHFGHAWYGNCY-UHFFFAOYSA-N

InChI=1S/C17H19N3.CH4O3S/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16;1-5(2,3)4/h1-10H,11-14H2,(H,18,19);1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula	CH4O3S
Molecular Weight	96.106
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C17H19N3
Molecular Weight	265.3529
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB08799
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68000865

Antazoline is an antagonist of histamine H1 receptors. It selectively bind to but does not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Antazoline in combination with naphazoline (VASOCON-A®) is indicated to relieve the symptoms of allergic conjunctivitis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 315 Target ID: CHEMBL3943 Sources: https://www.drugbank.ca/drugs/DB08799	Antagonist 2778		38.4 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Allergic conjunctivitis 100 Sources: http://www.empr.com/vasocon-a/drug/1227/	Palliative		Approved 8429	VASOCON-A Approved Use Temporary relief of ocular redness and itching. Launch Date 1990

PubMed

Title	Date	PubMed
Interactions of ligands at angiotensin II-receptors and imidazoline receptors.	2001 Feb	11286399
Inhibition of voltage-gated Ca2+ channels by antazoline.	2002 Oct 7	12395109
The effects of imidazoline agents on the aggregation of human platelets.	2004 Feb	15005880
Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands.	2009 Oct 23	19725810
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003

Patents

Sample Use Guides

In Vivo Use Guide

1-2 drops up to 4 times daily.

Route of Administration: Other

In Vitro Use Guide

The antihistaminic agent, antazoline, was tested for its ability to compete for [3H]pyrilamine, [3H]tiotidine and [3H]N-methyl histamine binding to rodent brain H1, H2 and H3 histamine receptors, respectively. Antazoline exhibited the highest affinity for H1-receptors (dissociation constant, Ki = 38.4 +/- 4.4 nM), and was considerably weaker at H2- (K1 = 44,433 +/- 1,763 nM) and H3-receptors (Ki = 42,400 +/- 7,527 nM).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:40:57 GMT 2023` Edited by `admin` on `Fri Dec 15 16:40:57 GMT 2023`
Record UNII	KU470J7TY6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ANTAZOLINE MESYLATE

Common Name

English

ANTAZOLINE MESILATE [MART.]

Common Name

English

NSC-7438

Code

English

N-BENZYL-N-(2-IMIDAZOLIN-2-YLMETHYL)ANILINE METHANESULFONATE

Systematic Name

English

ANTAZOLINE METHANESULPHONATE

Common Name

English

Antazoline mesilate [WHO-DD]

Common Name

English

ANTAZOLINE MESILATE

Common Name

English

N-BENZYL-N-(2-IMIDAZOLIN-2-YLMETHYL)ANILINE METHANESULPHONATE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29578